Aravive Inc

Aravive — Investor Presentation (October 2020)

25 slides from Aravive's investor presentation, Oct 8, 2020

  1. Slide 1: Corporate Presentation October 2020: Halting Disease Progression in its Tracks

    © 2020 Aravive, Inc. Corporate Presentation October 2020 Halting Disease Progression in its Tracks Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    © 2020 Aravive, Inc. Forward-Looking Statements This presentation contains forward-looking statements that may discuss Aravive’s plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward- looking statements generally i

  3. Slide 3: Developing Transformative Therapeutics for Cancer

    © 2020 Aravive, Inc. Developing Transformative Therapeutics for Cancer Clear Cell Renal Cell Carcinoma (ccRCC) Platinum Resistant Ovarian Cancer (PROC) Clinical Programs Uniquely Focused on GAS6/AXL Signaling Pathway Successfully Completed AVB-500 Phase 1 Trial in PROC Multiple Near-Term Development

  4. Slide 4: Urgent Needs in Ovarian and Renal Cancer

    © 2020 Aravive, Inc. Urgent Needs in Ovarian and Renal Cancer Ovarian Cancer 5th LEADING CAUSE OF DEATH among women in the U.S. ~70% OF PATIENTS are diagnosed with advanced disease 50% 5-YEAR relative survival LESS THAN Renal Cancer 15% 5-YEAR relative survival for metastatic renal cancer 70k NEW CA

  5. Slide 5: AVB-500: First-and Potential Best-In-Class Opportunity in Oncology

    © 2020 Aravive, Inc. AVB-500: First-and Potential Best-In-Class Opportunity in Oncology Ultra-high affinity decoy protein that targets the GAS6/AXL signaling pathway Neutralizes GAS6, starving tumors of signal that promotes growth, invasion, and metastasis Well-tolerated, with no unexpected dose-lim

  6. Slide 6: Deep Oncology Pipeline

    © 2020 Aravive, Inc. Indication Preclinical 3rd Oncology Phase 1 Phase 3 Phase 2 Phase 2a Phase 2b Anti-CTGF AVB-500 IST with AstraZeneca Phase 1b complete; plan to initiate Phase 2/3 trial in Q420 / Q121 OVARIAN CANCER platinum resistant (PAC or PLD combination) Recruiting OVARIAN CANCER platinum r

  7. Slide 7: Uniquely Focused on GAS6/AXL Signaling Pathway

    GAS6 and AXL are overexpressed in many cancers and associated with tumor growth, metastasis, drug resistance, and poor overall survival GAS6 is growth factor that regulates several biologic processes in cells through interaction with its receptors, including AXL, Tyro3, and Mer GAS6 is the sole acti

  8. Slide 8: Engineered Decoy Receptor is Best Approach for GAS6/AXL Inhibition

    © 2020 Aravive, Inc. COMPANY DRUG (STAGE) TARGET SELECTIVE FOR AXL Aravive AVB-500 (Ph Ib/II) GAS6 YES Astellas gilteritinib (Market; AML) AXL (Multi-kinase) NO Exelixis cabozantinib (Market; RCC & HCC) AXL (Multi-kinase) NO Mirati (BeiGene) sitravatinib (Ph III) AXL (Multi-kinase) NO Lilly merestin

  9. Slide 9: AVB-500 Phase 1b Trial Design in Platinum-Resistant Ovarian Cancer

    © 2020 Aravive, Inc. AVB-500 (AVB): q14 days Pegylated liposomal doxorubicin (PLD) 40 mg/m2 d1, or 28-day cycle paclitaxel (PAC): 80 mg/m2 day 1, day 8, day 15; Maintenance dosing on AVB-500 monotherapy AVB 500 10 mg/kg + PLD (N=21) AVB 500 15 mg/kg + PLD (N=2) Select RP2D AVB 500 10 mg/kg + PAC (N=

  10. Slide 10: Strong Safety Profile of AVB-500

    Safety report for trial AVB500-OC-002 generated by independent medical monitor concluded: “Based on a review of the safety data, no unexpected safety trends have been detected and the reported AE severity and frequency are consistent with expectations of the concomitant treatment (PAC or PLD) and th

  11. Slide 11: Promising Preliminary Efficacy Results in AVB-500 Phase 1b Trial in PROC

    © 2020 Aravive, Inc. Promising Preliminary Efficacy Results in AVB-500 Phase 1b Trial in PROC PAC patients with AVB-500 trough levels >MEC (N=14) had better response Higher response for AVB-500 plus PAC than published ORR of 10-15%1 Clinical activity of AVB-500 plus chemotherapy was more pronounced

  12. Slide 12: Selected Dose for AVB-500 Phase 2/3 Trial in PROC

    Selected 15 mg/kg Dose for AVB-500 Phase 2/3 Trial in PROC © 2020 Aravive, Inc. Consistent with hypothesis that trough levels are associated with clinical activity, all 5 evaluable patients in 15 mg/kg cohort achieved minimal efficacious concentration by their first CT scan, following four doses of

  13. Slide 13: Response Higher with AVB-500 + PAC than Historical Data

    INVESTIGATOR-ASSESSED BEST RESPONSE PER RECIST V1.1 PAC (N=23) PLD (N=26) CR 2 (8.7%) 0 PR 6 (26%) 4 (15%) ORR 8 (35%) 4 (15%) SD 6 (26%) 12 (46%) CBR 14 (61%) 16 (61.5%) PD 9 (39%) 10 (38.5%) 24% ORR across all dose cohorts (12/49 patients) 1 A. Davis et al. / Gynecologic Oncology 133 (2014) 624–63

  14. Slide 14: AVB-500 + Chemo Showed Improved Clinical Benefit in Later Lines of Therapy

    CLINICAL RESPONSE OF AVB-500+CHEMO IN 3L AND 4L CLINICAL RESPONSE OF CHEMOTHERAPY IN 3L AND 4L PER BRUCHIM ET AL, 2013 (N=99) 34 patients in AVB-500+chemo group overall; 20 patients in the high exposure AVB-500+chemo group; Two CRs in High Exposure Category Updated analysis based on all per protocol

  15. Slide 15: Improved Clinical Benefit in Patients with PFI < 3 Months

    CLINICAL RESPONSE OF CHEMOTHERAPY IN PATIENTS WITH <3MO PFI PER KOBAYASHI-KATO ET AL, 2019 (N=21) CLINICAL RESPONSE OF AVB-500+CHEMO IN PATIENTS WITH <3MO PFI ORR= objective response rate; SD=stable disease; CBR=clinical benefit rate; PD=progressive disease; PFI=platinum-free interval 16 patients in

  16. Slide 16: Target Lesions in ~70% of Patients were Stable or Reduced

    Target Lesions in ~70% of Patients were Stable or Reduced © 2020 Aravive, Inc. RESOLUTION OF TUMOR AFTER TREATMENT WITH AVB-500 Pre-treatment Omental Implant Post-AVB-500 Treatment Resolution (4 Months)

  17. Slide 17: Duration of Treatment by Trough above MEC

    Duration of Treatment by Trough above MEC: Patients with Higher Exposures Stayed on Treatment Longer © 2020 Aravive, Inc.

  18. Slide 18: Clinical Activity More Pronounced in Patients not Previously Treated with Bevacizumab

    AVB-500 + PAC PRIOR BEVACIZUMAB No Yes N 10 13 CR 2 (20%) 0 PR 4 (40%) 2 (15%) ORR 6 (60%) 2 (15%) SD 1 (10%) 5 (38%) CBR 7 (70%) 7 (54%) PD 3 (30%) 6 (46%) Third-Party Published Data as Benchmark (AURELIA Study1) Subgroup analysis of the control arms in the AURELIA (NCT00976911) bevacizumab study h

  19. Slide 19: Serum AXL/GAS6 Ratio Correlated with Response: Potential Biomarker

    sAXL/GAS6 >0.773 Yes NO N 14 7 CR 2 (14%) 0 PR 4 (28%) 0 ORR 6 (43%) 0 SD 2 (14%) 4 (57%) CBR 8 (57%) 4 (57%) PD 6 (43%) 3 (43%) sAXL not available for 2 patients Similar results seen in PLD combination Serum Levels of AXL/GAS6 Ratio Correlated with Response to AVB-500 + chemo Potential Biomarker: B

  20. Slide 20: Potential Registrational Study

    Potential Registrational Study Primary objective to assess anti-tumor activity of AVB-500 in combination with PAC as measured by PFS Patients with high-grade serous ovarian cancer only; not previously treated with bevacizumab Investigating adaptive designs / interim analyses exploring potential biom

  21. Slide 21: AVB-500 Phase 1b / Phase 2 Trial Design in ccRCC

    Phase 1b Trial of AVB-500 in Combination with Cabozantinib Up to 18 patients; ability to increase/decrease dose based on tolerability, PK/PD Phase 2 Controlled, Randomized, Blinded Trial Primary endpoint: PFS Secondary endpoints: ORR, DOR, DCR, and OS Histologically confirmed stage IV ccRCC progress

  22. Slide 22: Positioned for Long-Term Growth

    Q1 2020 Investigational New Drug Application open for ccRCC study Note: Above milestones may be impacted by COVID-19 Positioned for Long-Term Growth © 2020 Aravive, Inc. Mid-2020 Safety and PK from Ph1b PROC Q4 2020 P1b/P2 ccRCC initiation at 15 mg/kg Q4 2020 / Q1 2021 P2/P3 PROC initiation at 15 mg

  23. Slide 23: Financials and Capitalization

    © 2020 Aravive, Inc. NASDAQ: ARAV; Shares Outstanding*: 15.9M basic Cash and cash equivalents*: $60M Cash and cash equivalents expected to enable the company to fund its current operating plans into 2022 * As of June 30, 2020 Financials and Capitalization

  24. Slide 24: Developing Transformative Therapeutics for Cancer

    © 2020 Aravive, Inc. Developing Transformative Therapeutics for Cancer Clear Cell Renal Cell Carcinoma (ccRCC) Platinum Resistant Ovarian Cancer (PROC) Clinical Programs Uniquely Focused on GAS6/AXL Signaling Pathway Successfully Completed AVB-500 Phase 1 Trial in PROC Multiple Near-Term Development

  25. Slide 25: Halting Disease Progression in its Tracks

    © 2020 Aravive, Inc. Corporate Presentation October 2020 Halting Disease Progression in its Tracks

Aravive — Investor Presentation (October 2020) on 6ix